Skip to main content
NCBI home page
Heart logoLink to Heart
. 2001 Sep;86(3):336–340. doi: 10.1136/heart.86.3.336

Interleukin 1 receptor antagonist gene polymorphism and restenosis after coronary angioplasty

S Francis 1, N Camp 1, A Burton 1, R Dewberry 1, J Gunn 1, A Stephens-Lloyd 1, D Cumberland 1, A Gershlick 1, D Crossman 1
PMCID: PMC1729906  PMID: 11514491

Abstract

BACKGROUND—Percutaneous transluminal coronary angioplasty (PTCA) is limited by the recurrence of luminal stenosis, which occurs in up to 50% of procedures. It has been shown that patient specific factors, perhaps genes, contribute to this process.
OBJECTIVE—To determine whether completion of healing after PTCA is part of an acute self limiting inflammatory process and whether polymorphism at important inflammatory gene loci might determine susceptibility to restenosis after PTCA.
DESIGN—DNA samples were collected from 171 patients attending for elective PTCA in Sheffield (S) and Leicester (L), who were scheduled to undergo follow up angiography (at four months (L) or six months (S)) as part of other restenosis studies. At follow up angiography, the patients were separated into restenosers (> 50% luminal narrowing) and non-restenosers (< 50% luminal narrowing). Four DNA polymorphisms within interleukin 1 (IL-1) related loci (IL-1A (−889), IL-1B (−511), IL-1B (+3954), and IL-1RN intron 2 VNTR (variable number tandem repeat)) were genotyped using methods based on polymerase chain reaction. Significance was assessed by χ2 analysis of the relevant contingency table, and the magnitude of effect was estimated by calculating odds ratios. The Mantel-Haenszel (MH) test was applied to summarise data across the two populations.
RESULTS—Allele 2 at IL-1RN (IL-1RN*2) was significantly over represented in the non-restenoser group (L+S, 34% v 23% in restenosers). Furthermore, IL-1RN*2 homozygosity was increased in the non-restenoser population compared with the restenosers (MH test: p = 0.0196 (L+S); p = 0.031 (L+S, single vessel disease only), and the effect seemed to be restricted to the single vessel disease subpopulation. For other polymorphism within IL-1 related loci no significant associations were found with either restenosis or non-restenosis.
CONCLUSIONS—IL-1RN*2 may be associated with protection from restenosis after PTCA for individuals with single vessel disease. As this polymorphism has functional significance, this finding suggests that alteration in an individual's inflammatory predisposition may modulate the blood vessel response to injury.


Keywords: restenosis; inflammation; angioplasty; interleukin-1 receptor antagonist

Full Text

The Full Text of this article is available as a PDF (153.9 KB).

Figure 1  .

Figure 1  

Open in a new tab

Allele frequency of interleukin 1 receptor antagonist allele 2 (IL-1RN*2) in restenosers and non-restenosers (Sheffield (S) and Leicester (L)). Text box indicates the number of 11/12 and 22 homozygotes in the combined single vessel disease and multiple vessel disease cohort (L+S).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbate R., Marcucci R., Camacho-Vanegas O., Pepe G., Gori A. M., Capanni M., Simonetti I., Prisco D., Gensini G. F. Role of platelet glycoprotein PL(A1/A2) polymorphism in restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1998 Aug 15;82(4):524–525. doi: 10.1016/s0002-9149(98)00379-8. [DOI] [PubMed] [Google Scholar]
  2. Arend W. P. Interleukin-1 receptor antagonist. Adv Immunol. 1993;54:167–227. doi: 10.1016/s0065-2776(08)60535-0. [DOI] [PubMed] [Google Scholar]
  3. Chamberlain J., Gunn J., Francis S., Holt C., Crossman D. Temporal and spatial distribution of interleukin-1 beta in balloon injured porcine coronary arteries. Cardiovasc Res. 1999 Oct;44(1):156–165. doi: 10.1016/s0008-6363(99)00175-3. [DOI] [PubMed] [Google Scholar]
  4. Clay F. E., Tarlow J. K., Cork M. J., Cox A., Nicklin M. J., Duff G. W. Novel interleukin-1 receptor antagonist exon polymorphisms and their use in allele-specific mRNA assessment. Hum Genet. 1996 Jun;97(6):723–726. doi: 10.1007/BF02346180. [DOI] [PubMed] [Google Scholar]
  5. Cox A., Camp N. J., Nicklin M. J., di Giovine F. S., Duff G. W. An analysis of linkage disequilibrium in the interleukin-1 gene cluster, using a novel grouping method for multiallelic markers. Am J Hum Genet. 1998 May;62(5):1180–1188. doi: 10.1086/301817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Danis V. A., Millington M., Hyland V. J., Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol. 1995 Feb;99(2):303–310. doi: 10.1111/j.1365-2249.1995.tb05549.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dewberry R., Holden H., Crossman D., Francis S. Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis. Arterioscler Thromb Vasc Biol. 2000 Nov;20(11):2394–2400. doi: 10.1161/01.atv.20.11.2394. [DOI] [PubMed] [Google Scholar]
  8. Dinarello C. A. Interleukin-1 and interleukin-1 antagonism. Blood. 1991 Apr 15;77(8):1627–1652. [PubMed] [Google Scholar]
  9. Elhage R., Maret A., Pieraggi M. T., Thiers J. C., Arnal J. F., Bayard F. Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice. Circulation. 1998 Jan 27;97(3):242–244. doi: 10.1161/01.cir.97.3.242. [DOI] [PubMed] [Google Scholar]
  10. Francis S. E., Camp N. J., Dewberry R. M., Gunn J., Syrris P., Carter N. D., Jeffery S., Kaski J. C., Cumberland D. C., Duff G. W. Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. Circulation. 1999 Feb 23;99(7):861–866. doi: 10.1161/01.cir.99.7.861. [DOI] [PubMed] [Google Scholar]
  11. Kasi J. C., Zhang Y., Calvino R., Vazquez-Rodriguez J. M., Castro-Beiras A., Jeffery S., Carter N. Angiotensin-converting enzyme insertion/deletion polymorphism and restenosis after coronary angioplasty in unstable angina pectoris. Am J Cardiol. 1996 Apr 15;77(10):875–877. doi: 10.1016/s0002-9149(97)89187-4. [DOI] [PubMed] [Google Scholar]
  12. Kastrati A., Koch W., Berger P. B., Mehilli J., Stephenson K., Neumann F. J., von Beckerath N., Böttiger C., Duff G. W., Schömig A. Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. J Am Coll Cardiol. 2000 Dec;36(7):2168–2173. doi: 10.1016/s0735-1097(00)01014-7. [DOI] [PubMed] [Google Scholar]
  13. Lehmann K. G., Melkert R., Serruys P. W. Contributions of frequency distribution analysis to the understanding of coronary restenosis. A reappraisal of the gaussian curve. Circulation. 1996 Mar 15;93(6):1123–1132. doi: 10.1161/01.cir.93.6.1123. [DOI] [PubMed] [Google Scholar]
  14. Mamotte C. D., van Bockxmeer F. M., Taylor R. R. PIa1/a2 polymorphism of glycoprotein IIIa and risk of coronary artery disease and restenosis following coronary angioplasty. Am J Cardiol. 1998 Jul 1;82(1):13–16. doi: 10.1016/s0002-9149(98)00235-5. [DOI] [PubMed] [Google Scholar]
  15. Mandrup-Poulsen T., Pociot F., Mølvig J., Shapiro L., Nilsson P., Emdal T., Røder M., Kjems L. L., Dinarello C. A., Nerup J. Monokine antagonism is reduced in patients with IDDM. Diabetes. 1994 Oct;43(10):1242–1247. doi: 10.2337/diab.43.10.1242. [DOI] [PubMed] [Google Scholar]
  16. Nicklin M. J., Hughes D. E., Barton J. L., Ure J. M., Duff G. W. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med. 2000 Jan 17;191(2):303–312. doi: 10.1084/jem.191.2.303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ohishi M., Fujii K., Minamino T., Higaki J., Kamitani A., Rakugi H., Zhao Y., Mikami H., Miki T., Ogihara T. A potent genetic risk factor for restenosis. Nat Genet. 1993 Dec;5(4):324–325. doi: 10.1038/ng1293-324. [DOI] [PubMed] [Google Scholar]
  18. Pietersma A., Kofflard M., de Wit L. E., Stijnen T., Koster J. F., Serruys P. W., Sluiter W. Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment. Circulation. 1995 Mar 1;91(5):1320–1325. doi: 10.1161/01.cir.91.5.1320. [DOI] [PubMed] [Google Scholar]
  19. Samani N. J., Martin D. S., Brack M., Cullen J., Chauhan A., Lodwick D., Harley A., Swales J. D., de Bono D. P., Gershlick A. H. Insertion/deletion polymorphism in the angiotensin-converting enzyme gene and risk of restenosis after coronary angioplasty. Lancet. 1995 Apr 22;345(8956):1013–1016. doi: 10.1016/s0140-6736(95)90756-4. [DOI] [PubMed] [Google Scholar]
  20. Samani N. J., Martin D. S., Brack M., Cullen J., Wallis R., Lodwick D., Chauhan A., Harley A., Thompson J. R., Gershlick A. H. Apolipoprotein E polymorphism does not predict risk of restenosis after coronary angioplasty. Atherosclerosis. 1996 Sep 6;125(2):209–216. doi: 10.1016/0021-9150(96)05879-0. [DOI] [PubMed] [Google Scholar]
  21. Serrano C. V., Jr, Ramires J. A., Venturinelli M., Arie S., D'Amico E., Zweier J. L., Pileggi F., da Luz P. L. Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty. J Am Coll Cardiol. 1997 May;29(6):1276–1283. doi: 10.1016/s0735-1097(97)00070-3. [DOI] [PubMed] [Google Scholar]
  22. Symons J. A., Young P. R., Duff G. W. Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist. Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1714–1718. doi: 10.1073/pnas.92.5.1714. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Völzke H., Hertwig S., Rettig R., Motz W. The angiotensinogen gene 235T variant is associated with an increased risk of restenosis after percutaneous transluminal coronary angioplasty. Clin Sci (Lond) 2000 Jul;99(1):19–25. [PubMed] [Google Scholar]
  24. Weintraub W. S., Brown C. L., Liberman H. A., Morris D. C., Douglas J. S., Jr, King S. B., 3rd Effect of restenosis at one previously dilated coronary site on the probability of restenosis at another previously dilated coronary site. Am J Cardiol. 1993 Nov 15;72(15):1107–1113. doi: 10.1016/0002-9149(93)90977-k. [DOI] [PubMed] [Google Scholar]
  25. Wilkinson R. J., Patel P., Llewelyn M., Hirsch C. S., Pasvol G., Snounou G., Davidson R. N., Toossi Z. Influence of polymorphism in the genes for the interleukin (IL)-1 receptor antagonist and IL-1beta on tuberculosis. J Exp Med. 1999 Jun 21;189(12):1863–1874. doi: 10.1084/jem.189.12.1863. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES